Green Light For First OTC Naloxone In US After FDA Raises Caution Flag During Advisory Panel
Executive Summary
Sponsor Emergent revealed single-panel display of instructions at February advisory panel without testing in OTC human factors study. While different naloxone formulations and dosages will remain Rx-only, generics of the Narcan 4-mg nasal spray must transition to OTC, FDA says.
You may also be interested in...
New Opioid Labeling Further Constrains Use, Urges Prescribing Only By Docs ‘Knowledgeable’ About Risks
US FDA’s mandated labeling changes come after the agency required manufacturers to provide mail-back envelopes for opioid disposal.
Keeping Track: More Rx-To-OTC Switches On Deck After US FDA’s OTC Narcan Approval; Iovance Looks To Bring Cell Therapy To Melanoma
The latest drug development news and highlights form the Pink Sheet’s US FDA Performance Tracker.
Emergent’s OTC Naloxone Single-Panel Instruction List Prompts Doubletake From US FDA Officials
Larger box “would accommodate all five steps on the single back panel,” says Emergent executive Manish Vyas. But FDA says proposed DFl for OTC Narcan nasal spray “has not yet been officially submitted or reviewed.”